STOCKHOLM, SWEDEN - November 8, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders is pleased to invite investors, analysts and media to a webinar on November 10 at CET 11.00 - 12.00. The event will only be digital.

STOCKHOLM, SWEDEN - November 8, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced on Monday November 7 that it has initiated a collaboration with Johnson & Johnson Consumer Health Inc. to develop  a unique AI-based screening tool to predict the development of a common type of eczema called atopic dermatitis in infants.

November 7, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that it has signed an agreement with Johnson & Johnson Consumer Inc. to collaborate on the development of a unique AI-based screening tool to predict the development of a common type of eczema called atopic dermatitis in infants.

STOCKHOLM, SWEDEN, - October 27, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a recently published article in the journal "Molecular Psychiatry", a part of Nature, named "Ectodermal origins of the skin-brain axis: a novel model for the developing brain, inflammation, and neurodevelopmental conditions"  discusses that EIS may represent an alternate clinical measure of skin barrier integrity that may function as a surrogate for neurodevelopmental divergence.

STOCKHOLM, SWEDEN, - October 26, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new clinical study has been published presenting the improvement that the Nevisense test provides over standard of care visual and dermoscopic evaluation. The article named "Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy" has been published in the journal "Melanoma Research". The study included 231 US Dermatologists making a total of 33.957 biopsy decisions. The study participants showed a statistically significant improvement in correct biopsy decisions beyond their dermoscopic evaluation when integrating the Nevisense result. With Nevisense, Dermatologists identified more melanomas for biopsy; their sensitivity increasing from 85.2% to 91.1%.

Dharminder Chahal (VanHerk Group)

Peter Elmvik (Stockholms Elbolag),

Iraj Arastoupour,

Tord Lendau (Chairman of the Board).